Chemoprophylaxis
(Duration: Variesb)
75 mg capsule once a day × ≥10 daysc
≤15 kg
30 mg once daily
× 10 daysc
15–23 kg
45 mg once daily
× 10 daysc
>23–40 kg
60 mg once daily
× 10 daysc
>40 kg
75 mg once daily
× 10 daysc
Safety and efficacy not established for prophylaxis in infants <1 y
2 inhalations (10 mg) once a day × 10 days (28 days for outbreak)
≥5 y
2 inhalations (10 mg) once a day × 10 days (28 days for outbreak)
b
c
See also "Antivirals for Chemoprophylaxis" and "Outbreak Management in Institutional Settings."
Up to 6 weeks during a community outbreak.
ÎÎAll residents with laboratory-confirmed influenza virus infection
should be treated with an appropriate influenza antiviral medication.
After 1 case of laboratory-confirmed influenza is detected in a facility
resident, all persons in the facility subsequently developing influenzalike illness or other signs or symptoms consistent with influenza
(eg, isolated altered mental status in an elderly resident) should be
considered for treatment with an influenza antiviral medication (A-III).
ÎFor all institutional employees who are unable to receive influenza
Î
vaccine or in whom the vaccine is contraindicated, or when the vaccine
is expected to be ineffective, antiviral medications should be used for
chemoprophylaxis (B-III).
ÎÎAntiviral chemoprophylaxis should be continued for 14 days or
for 7 days after the onset of symptoms in the last person infected,
whichever is longer (A-II).
11
